Historical azn News Stories
AZN Soars: $2B U.S. Build & FDA Breast Drug Nod Up
AstraZeneca announced a $2 billion U.S. manufacturing expansion and secured FDA approvals for Datroway (Dato‑DXd) and an expanded Calquence indication. These concrete developments drove AZN to fresh 52‑week highs, underpinned by strengthened production capacity and near‑term commercial catalysts.
AstraZeneca Baxdrostat Win Fuels AZN Nasdaq Surge!
AstraZeneca’s recent Phase III success with baxdrostat, stronger-than-expected Q3 results, and a harmonized listing plan have driven AZN to a one‑year high on the Nasdaq‑100. This article explains the concrete catalysts, operational moves, and near‑term implications for investors.
AstraZeneca $4.5B Virginia Plant Fuels Stock Rally
AstraZeneca's latest week of news — stronger-than-expected Q3 results, a $4.5B Virginia manufacturing commitment, a U.S. government pricing agreement and approval for a direct NYSE listing — pushed AZN higher. Analyst upgrades and unusual options volume added fuel. This article explains the key events, why they matter for investors, and risks to monitor.
AZN: Datroway Gets Second FDA Nod; China Pact $5B
AstraZeneca secured an accelerated FDA approval for Datroway in EGFR‑mutated NSCLC, reaffirming its ADC momentum after earlier breast‑cancer approval. The company also struck a roughly $5 billion research pact with CSPC in China and reported encouraging Phase III data for camizestrant. These concrete developments—plus milestone obligations to Daiichi Sankyo—de‑risk select pipeline assets and provide specific near‑term catalysts for AZN.